How the US Food and Drug Administration’s approval of aducanumab for Alzheimer's disease has implication for oncology and beyond
File(s)Viewpoint - aducanumab for EJC.docx (60.37 KB)
Accepted version
Author(s)
Lythgoe, Mark P
Prasad, Vinay
Type
Journal Article
Date Issued
2021-11
Date Acceptance
2021-08-11
Citation
European Journal of Cancer, 2021, 157, pp.68-70
ISSN
0959-8049
Publisher
Elsevier BV
Start Page
68
End Page
70
Journal / Book Title
European Journal of Cancer
Volume
157
Copyright Statement
© 2021 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
https://www.sciencedirect.com/science/article/pii/S0959804921005293?via%3Dihub
Subjects
Oncology & Carcinogenesis
1112 Oncology and Carcinogenesis
1117 Public Health and Health Services
Publication Status
Published
Date Publish Online
2021-09-04